Does low-dose botulinum toxin help the recovery of arm function when given early after stroke? A phase II randomized controlled pilot study to estimate effect size

Abstract

Objective: Spasticity after stroke may be associated with worse functional outcome. Our study aim is to establish whether a low dose of botulinum toxin, given early post stroke before clinically evident spasticity warrants treatment, will improve recovery of arm function.

Design: A double-blind randomized placebo-controlled trial.

Setting: An acute stroke unit.

Subjects: Individuals recruited within three weeks of stroke onset with severe arm function deficits.

Interventions: Injections of quarter and half standard dose botulinum toxin A to the upper limb, with a control of normal saline injections.

Main measures: Arm function, active and passive movement, and spasticity at elbow and wrist were recorded at baseline, and at 4, 8, 12 and 20 weeks post intervention. A pre-planned subgroup analysis included only subjects with no arm function at baseline (Action Research Arm Test score = 0).

Results: Thirty subjects were recruited, and 21 completed all assessments. Arm function scores improved in all three groups between baseline and week 20. There was no benefit for active treatment over control in the whole group analysis. In the subgroup analysis the active groups improved when compared with the control group and effect sizes for improvement in this subgroup were 0.6 and 0.5 for the quarter dose and half dose groups respectively.

Conclusions: Individuals with no arm function within three weeks of stroke may benefit functionally from botulinum toxin. Using the effect size of 0.5, further studies would need a minimum of 101 participants in each group to confirm this finding.

Get full access to this article

View all access options for this article.

References

Pandyan AD , Gregoric M. , Barnes MP et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil 2005; 27: 2-6.

Sommerfeld DK , Elsy U-B. , Svensson A-K. , Holmqvist LW , von Arbon MH Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke 2004; 35: 134-39.

Watkins CL , Leathley MJ , Gregson JM , Moore AP , Smith TL , Sharma AK Prevalence of spasticity post stroke. Clin Rehabil 2002; 16: 515-22.

Malhotra S. , Cousins E. , Ward A. et al. An investigation into the agreement between clinical, biomechanical and neurophysiological measures of spasticity. Clin Rehabil 2008; 22: 1105-15.

Barnes MP , Johnson GR. eds. Upper motor neurone syndrome and spasticity: clinical management and neurophysiology. Cambridge, Cambridge University Press, 2001.

Ada L. , O’Dwyer N. , O’Neill E. Relation between spasticity, weakness and contracture of the elbow flexors and upper limb activity after stroke: an observational study. Disabil Rehabil 2006; 28: 891-97.

Royal College of Physicians Working Party. Concise guidelines to good practice. Guidelines for the use of botulinum toxin in the management of spasticity in adults. Salisbury, Royal College of Physicians of London, July 2002.

Ward AB A summary of spasticity management- a treatment algorithm. Eur J Neurol 2002; 9(suppl 1): 48-52.

De Paiva A. , Meunier FA , Molgó J. , Aoki KR , Dolly JO Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999; 96: 3200-205.

10.

Pandyan AD , Cameron M. , Powell J. , Stott DJ , Granat MH Contractures in the post-stroke wrist: a pilot study of its time course of development and its association with upper limb recovery. Clin Rehabil 2003; 17: 88-95.

11.

Sheaan GL

Botulinum treatment of spasticity: why is it so difficult to show a functional benefit?

Curr Opin Neurol 2001 ; 14: 771-76.

12.

Pandyan AD , Price CIM , Barnes MP , Johnson GR A biomechanical investigation into the validity of the Modified Ashworth Scale as a measure of elbow spasticity. Clin Rehabil 2003; 17: 290-94.

13.

Pandyan AD , Johnson GR , Price CIM , Curless RH , Barnes MP A review of the properties and limitations of the Ashworth and Modified Ashworth Scales as measures. Clin Rehabil 1999; 13: 373-83.

14.

Bakheit AMO , Thilmann AF , Ward AB et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke . Stroke 2000; 31: 2402-406.

15.

Childers MK , Brashear A. , Jozefczyk P. et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke . Arch Phys Med Rehabil 2004; 85: 1063-69.

16.

Suputtitada A. , Suwanwela NC The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil Rehabil 2005; 27: 176-84.

17.

Leathley MJ , Gregson JM , Moore AP , Smith TL , Sharma AK , Watkins CL Predicting spasticity after stroke in those surviving to 12 months. Clin Rehabil 2004; 18: 438-43.

18.

Lyle RC A performance test for assessment of upper limb function in physical rehabilitation treatment and research. Int J Rehabil Res 1981; 4: 483-92.

19.

Falciglia G. , O’Connor J. , Gedling E. Upper arm anthropometric norms in elderly white subjects. J Am Diet Assoc 1988; 88: 569-74.

20.

Hermens HJ , Freriks B. , Merletti R. et al. SENIAM:European recommendations for surface electromyography. Roessingh, Roessingh Research and Development , 1999.

21.

Van der Lee JH , Wagenaar RC , Lankhorst GJ , Vogelaar TW , Devillé WL , Bouter LM Forced use of the upper extremity in chronic stroke patients: results from a single-blind randomized clinical trial. Stroke 1999; 30: 2369-75.

22.

Pandyan AD , Vuadens P. , van Wijck FMJ , Stark S. , Johnson GR , Barnes MP Are we underestimating the clinical efficacy of botulinum toxin (type A)? Quantifying changes in spasticity, strength and upper limb function after injections of Botox to the elbow flexors in a unilateral stroke population . Clin Rehabil 2002; 16: 654-60.

23.

Simpson DM , Alexander DN , O’Brien CF et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996; 46: 1306-10.

24.

Blanton S. , Morris DM , Prettyman MG et al. Lessons learned in participant recruitment and retention: the EXCITE trial. Phys Ther 2006; 86: 1520-33.

25.

Burridge JH , Wood DE , Hermens HJ et al. Theoretical and methodological considerations in the measurement of spasticity. Disabil Rehabil 2005; 27: 69-80.